**Name of Journal:** *World Journal of Virology*

**Manuscript NO:** 77239

**Manuscript Type:** LETTER TO THE EDITOR

**Possible agent for COVID-19** **treatment: Rifampicin**

Aydin OC *et al*. Rifampicin to treat COVID-19

Ozlem Celik Aydin, Sonay Aydın, Sureyya Barun

**Ozlem Celik Aydin,** Department of Medical Pharmacology, Erzincan University, Mengucek Gazi Education and Research Hospital, Erzincan 24100, Turkey

**Sonay Aydın, Sureyya Barun,** Department of Pharmacology, Gazi University, Ankara 06500, Turkey

**Sonay Aydın,** Department of Radiology, Erzincan University, Erzincan 24100, Turkey

**Author contributions:** Aydın S, Aydin OC and Barun S conceived the study; Aydın S, Aydin OC and Barun S were responsible for designing, materials and supervision; Aydın S, Aydin OC and Barun S did the literature search, wrote the manuscript, and reviewed the manuscript critically; All authors have read and approved the final manuscript.

**Corresponding author: Ozlem Celik Aydin, MD, Doctor,** Department of Medical Pharmacology, Erzincan University, Mengucek Gazi Education and Research Hospital, Başbağlar Mahallesi Hacı Ali Akın Caddesi No. 32 Erzincan/Merkez, Erzincan 24100, Turkey. ozlemclk\_89@hotmail.com

**Received:** April 20, 2022

**Revised:** June 20, 2022

**Accepted:** **August 25, 2022**

**Published online:**

**Abstract**

Rifampicin is a promising drug for the treatment of coronavirus disease 2019 based on its antiviral properties and recent *in silico* studies. *In silico* studies can serve as a foundation for further studies.

**Key Words:** Rifampicin; COVID-19; Treatment; *In silico*; Drug-drug interaction; Therapeutic potential

Aydin OC, Aydın S, Barun S. Possible agent for COVID-19 treatment: Rifampicin. *World J Virol* 2022; In press

**Core Tip:** Rifampicin may be used as a treatment for coronavirus disease 2019 (COVID-19). Although it has a variety of drug-drug interactions, none of the important ones for the currently utilised COVID-19 medicines, favipiravir, enoxaparin, and aspirin, have been defined.

**TO THE EDITOR**

We read the review written by Panayiotakopoulos and Papadimitriou[1]with interest. The impacts of the coronavirus disease 2019 (COVID-19) pandemic are still being felt, and research into this topic continues due to the lack of a precise therapy. It is feasible to repurpose medications already used for other reasons for the treatment of COVID-19. The authors discussed rifampicin’s antiviral capabilities, its potential effects in computer simulations, its safety, and its role in clinical practice. Rifampicin is an antibacterial drug that inhibits DNA-dependent RNA polymerase in *Mycobacterium**tuberculosis*, and its antiviral effect has been shown on some viruses[2]. On this basis, the potential efficacy of rifampicin as a COVID-19 treatment drug has been demonstrated in *in silico* research[3]. We concur with the authors’ suggestion for more research into the potential use of rifampicin for COVID-19.

In a study in which 20 United States Food and Drug Administration (FDA)-approved drugs were screened by molecular docking method in a possible drug design for COVID-19, rifampicin showed *in silico* binding to more than one target protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). Other macrocyclic antibiotics showing binding are polymyxin B and bafilomycin A[4]. In another *in silico* study of FDA-approved drugs to treat COVID-19 infection, rifampicin has stronger binding affinity for the COVID-19 main protease Mpro[5]. However, additional studies are needed for validation.

Due to the properties of rifampicin, various drug-drug interactions (DDIs) may occur during its possible use. Rifampicin promotes the expression of cytochrome p450 3A4 (CYP3A4) in the small intestine and liver, as noted in the review. Additionally, according to the work by Panayiotakopoulos and Papadimitriou[1], an essential feature of rifampicin is that it activates proteins such as the P glycoprotein (P-gp) drug transporter and CYP2C-mediated metabolism[6]. There are possible DDIs with drugs used for the treatment of COVID-19 and for additional diseases. Favipiravir is one of the antiviral medications used for the treatment of COVID-19. It is metabolized mostly *via* aldehyde oxidase and xanthine oxidase[7], and the probability of a pharmacological interaction between rifampicin and favipiravir is low. Lopinavir and ritonavir are two additional widely used antivirals; coadministration of these drugs with rifampin may result in a decrease in the plasma concentrations of ritonavir and lopinavir due to rifampin’s induction of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of ritonavir and lopinavir[8]. Remdesivir is widely used for COVID-19 treatment, which is metabolized through hydrolysis reaction to its triphosphate active form *via* by carboxylesterase 1 (80%), cathepsin A (10%), and CYP3A (10%). Since rifampicin is a potential inductor of CYP3A4, concomitant administration might increase the metabolism of remdesivir[9]. Dexamethasone has a strong anti-inflammatory impact and is typically used as an adjunctive treatment for COVID-19 pneumonia. Rifampin may increase corticosteroid hepatic metabolism, hence diminishing their therapeutic impact. Corticosteroids’ half-life of elimination is shortened by up to 45% when co-administered with rifampin[10,11].

It has been suggested that prophylaxis of thrombosis in COVID-19 should include both anticoagulant and antiplatelet medications. Enoxaparin and aspirin are the two most often used anticoagulant and antiplatelet medications[12]. Fortunately, no significant medication interactions between these drugs and rifampicin have been identified. Apixaban and other direct oral anticoagulants can also be utilised. Rifampicin coadministration significantly increased apixaban plasma concentrations. When used orally, approximately 15% of apixaban is metabolised by CYP3A and roughly 6% by CYP1A2 and CYP2J2. The balance (50%) is eliminated unaltered in the form of faeces and urine. A single dose of rifampicin decreased apixaban clearance by 25%. Rifampicin largely influences apixaban absorption (and/or distribution), which could be attributed to an impairment of intestinal P-gp[13].

The authors said that rifampicin has been shown to be quite effective in treating COVID-19 in *in silico* tests. Additionally, multiple medication classes have been examined *in silico* for the treatment of COVID-19. Melatonin, ramelteon, and agomelatine, for example, have been demonstrated to significantly limit virus entry into cells in investigations. Ramelteon was proven to be the most effective antiviral against SARS-CoV-2[14].

**REFERENCES**

1 **Panayiotakopoulos GD**, Papadimitriou DT. Rifampicin for COVID-19. *World J Virol* 2022; **11**: 90-97 [PMID: 35433334 DOI: 10.5501/wjv.v11.i2.90]

2 **Abulfathi AA**, Decloedt EH, Svensson EM, Diacon AH, Donald P, Reuter H. Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis. *Clin Pharmacokinet* 2019; **58**: 1103-1129 [PMID: 31049868 DOI: 10.1007/s40262-019-00764-2]

3 **Kumar A**, Mishra DC, Angadi UB, Yadav R, Rai A, Kumar D. Inhibition Potencies of Phytochemicals Derived from Sesame Against SARS-CoV-2 Main Protease: A Molecular Docking and Simulation Study. *Front Chem* 2021; **9**: 744376 [PMID: 34692642 DOI: 10.3389/fchem.2021.744376]

4 **Elmorsy MA**, El-Baz AM, Mohamed NH, Almeer R, Abdel-Daim MM, Yahya G. In silico screening of potent inhibitors against COVID-19 key targets from a library of FDA-approved drugs. *Environ Sci Pollut Res Int* 2022; 29: 12336-12346 [PMID: 34562220 DOI: 10.1007/s11356-021-16427-4]

5 **Pathak Y**, Mishra A, Tripathi V. Rifampicin may be repurposed for COVID-19 treatment: Insights from an in-silico study. *Research Square* 2020 [DOI: 10.21203/rs.3.rs-22546/v1]

6 **Niemi M**, Backman JT, Fromm MF, Neuvonen PJ, Kivistö KT. Pharmacokinetic interactions with rifampicin : clinical relevance. *Clin Pharmacokinet* 2003; **42**: 819-850 [PMID: 12882588 DOI: 10.2165/00003088-200342090-00003]

7 **Du YX**, Chen XP. Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection. *Clin Pharmacol Ther* 2020; **108**: 242-247 [PMID: 32246834 DOI: 10.1002/cpt.1844]

8 **American Thoracic Society**; CDC; Infectious Diseases Society of America. Treatment of tuberculosis. *MMWR Recomm Rep* 2003; **52**: 1-77 [PMID: 12836625]

9 **Deb S**, Reeves AA, Hopefl R, Bejusca R. ADME and Pharmacokinetic Properties of Remdesivir: Its Drug Interaction Potential. *Pharmaceuticals (Basel)* 2021; **14** [PMID: 34358081 DOI: 10.3390/ph14070655]

10 **Lee KH**, Shin JG, Chong WS, Kim S, Lee JS, Jang IJ, Shin SG. Time course of the changes in prednisolone pharmacokinetics after co-administration or discontinuation of rifampin. *Eur J Clin Pharmacol* 1993; **45**: 287-289 [PMID: 8276057 DOI: 10.1007/BF00315399]

11 **Ahmed MH**, Hassan A. Dexamethasone for the Treatment of Coronavirus Disease (COVID-19): a Review. *SN Compr Clin Med* 2020; **2**: 2637-2646 [PMID: 33163859 DOI: 10.1007/s42399-020-00610-8]

12 **Aydin S**, Kantarci M, Karavas E, Unver E, Yalcin S, Aydin F. Lung perfusion changes in COVID-19 pneumonia: a dual energy computerized tomography study. *Br J Radiol* 2021; **94**: 20201380 [PMID: 34415201 DOI: 10.1259/bjr.20201380]

13 **Mikus G**, Foerster KI, Schaumaeker M, Lehmann ML, Burhenne J, Haefeli WE. Application of a microdosed cocktail of 3 oral factor Xa inhibitors to study drug-drug interactions with different perpetrator drugs. *Br J Clin Pharmacol* 2020; **86**: 1632-1641 [PMID: 32159869 DOI: 10.1111/bcp.14277]

14 **Yadalam PK**, Balaji TM, Varadarajan S, Alzahrani KJ, Al-Ghamdi MS, Baeshen HA, Alfarhan MFA, Khurshid Z, Bhandi S, Jagannathan R, Patil VR, Raj AT, Ratnayake J, Patil S. Assessing the therapeutic potential of agomelatine, ramelteon, and melatonin against SARS-CoV-2. *Saudi J Biol Sci* 2022; **29**: 3140-3150 [PMID: 35095308 DOI: 10.1016/j.sjbs.2022.01.049]

**Footnotes**

**Conflict-of-interest statement:** The authors have no conflicts of interest to declare.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** April 20, 2022

**First decision:** June 8, 2022

**Article in press:**

**Specialty type:** Pharmacology and Pharmacy

**Country/Territory of origin:** Turkey

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Gupta S, United States; Varshney K, Australia **S-Editor:** Gong ZM **L-Editor:** Filipodia **P-Editor:** Gong ZM